What is the recommended dosing regimen for losartan (angiotensin II receptor antagonist)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 23, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Losartan Dosing Recommendations

The recommended starting dose of losartan for adult hypertension is 50 mg once daily, with titration to a maximum dose of 100 mg once daily as needed for blood pressure control. 1

Adult Dosing by Indication

Hypertension

  • Starting dose: 50 mg once daily 1
  • Maximum dose: 100 mg once daily 1
  • For patients with possible intravascular depletion (e.g., on diuretic therapy): Starting dose of 25 mg once daily 1
  • For patients with mild-to-moderate hepatic impairment: Starting dose of 25 mg once daily 1

Hypertension with Left Ventricular Hypertrophy

  • Starting dose: 50 mg once daily 1
  • Titration: Increase to 100 mg once daily based on blood pressure response 1
  • Consider adding hydrochlorothiazide 12.5 mg daily with potential increase to 25 mg daily 1

Nephropathy in Type 2 Diabetes

  • Starting dose: 50 mg once daily 1
  • Target dose: 100 mg once daily 1

Heart Failure

  • Target dose: 150 mg once daily 2
  • Starting dose: 50 mg once daily 2
  • Evidence suggests higher doses (150 mg daily) provide better cardiovascular outcomes than lower doses 2
  • The HEAAL trial demonstrated that 150 mg daily of losartan was superior to 50 mg daily, with a relative risk reduction of 10% in death or heart failure hospitalization 3

Pediatric Dosing for Hypertension

  • Starting dose: 0.7 mg/kg once daily (up to 50 mg total) 1
  • Maximum dose: 1.4 mg/kg once daily (not to exceed 100 mg daily) 1
  • Not recommended for children under 6 years of age or with estimated GFR < 30 mL/min/1.73 m² 1

Dosing Considerations and Adjustments

Titration Schedule

  • Adjust therapy no more frequently than every 2 weeks to target doses or maximally tolerated doses 2
  • Losartan can be administered without regard to food 4

Special Populations

  • No dosage adjustment necessary based on age, sex, or race 4
  • No dosage adjustment necessary in patients with renal insufficiency 4
  • Losartan is not removed during hemodialysis 4
  • Contraindicated in pregnancy 4

Clinical Evidence Supporting Higher Doses

  • For diabetic nephropathy, 100 mg daily was significantly more effective than 50 mg daily in reducing albuminuria (48% vs 30% reduction) without additional benefit at 150 mg 5
  • For non-diabetic patients with nephrotic range proteinuria, 100 mg daily provided optimal antiproteinuric effect (-30%) compared to 50 mg (-13%) with no additional benefit at 150 mg 6
  • Higher doses of losartan (100 mg) are recommended for optimal clinical efficacy in hypertension, heart failure, and renal diseases 7

Common Pitfalls and Caveats

  • Avoid simultaneous use with ACE inhibitors due to increased risk of hyperkalemia and renal dysfunction 2
  • Monitor for symptomatic hypotension in volume-depleted patients 1
  • Losartan is metabolized primarily by CYP3A4, 2C9, and 2C10 isoenzymes, but has a favorable drug-drug interaction profile 4
  • The 50 mg dose, while commonly prescribed, may be suboptimal for many patients, particularly those with heart failure or proteinuric kidney disease 7

References

Guideline

Optimal Dosing of Losartan for Hypertension and Heart Failure

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Clinical pharmacokinetics of losartan.

Clinical pharmacokinetics, 2005

Research

Optimal dose of losartan for renoprotection in diabetic nephropathy.

Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, 2002

Research

Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria.

American journal of kidney diseases : the official journal of the National Kidney Foundation, 2001

Research

Pharmacokinetic evaluation of losartan.

Expert opinion on drug metabolism & toxicology, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.